Haoxi Health Raises $6.5M in Direct Offering via Univest

Event summary

  • Univest Securities closed a $6.5M registered direct offering for Haoxi Health Technology Ltd on May 12, 2026.
  • The offering included 9M Class A shares and 16.99M pre-funded warrants at $0.25 per share.
  • Proceeds will be used for general corporate purposes after deducting placement agent fees.
  • The offering was conducted under a shelf registration statement on Form F-3, effective since June 2025.

The big picture

This capital raise reflects the growing demand for specialized digital marketing solutions in China's healthcare sector. Univest's role as placement agent underscores its focus on cross-border transactions in the technology space. The deal size, while modest, signals continued investor interest in niche digital marketing players despite broader market volatility.

What we're watching

Capital Deployment
How Haoxi Health will allocate the $6.5M proceeds to drive growth in China's competitive digital marketing space.
Market Positioning
Whether the capital raise strengthens Haoxi's competitive edge against larger platforms in short-form video and news feed advertising.
Regulatory Compliance
The pace at which Haoxi can navigate U.S. and Chinese regulatory requirements following this cross-border capital raise.

Related topics

Technology